Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Lipidomics in (SIDS) Sudden Infant Death Syndrome (Study ST000673)

C18 NEGATIVE ION MODE (Analysis AN001032)

Metabolite	Structure	F1	F2
PE 40:8; [M-H]-@6.00	ME185640	0.51	1.21
PI 40:6; [M-H]-@5.76	ME185668	0.54	1.20
plasmenyl-PE 36:5; [M-H]-@6.36	ME185691	0.61	1.17
PI 36:2; [M-H]-@5.85	ME185660	0.57	1.18
PE 34:4; [M-H]-@5.76	ME185623	0.58	1.18
PI 34:2; [M-H]-@5.21	ME185659	0.59	1.18
PS 38:5; [M-H]-@5.47	ME185676	0.89	1.05
plasmenyl-PE 42:4; [M-H]-@8.28	ME185700	0.89	1.05
PI 38:5; [M-H]-@5.32	ME185665	0.89	1.05
PE 40:4; [M-H]-@7.48	ME185638	0.89	1.05
PG 34:2; [M-H]-@5.31	ME185646	0.89	1.05
PE 35:2; [M-H]-@6.77	ME185626	0.87	1.06
PC 28:0; [M-Ac-H]-@5.44	ME185594	0.87	1.06
PC 35:4; [M-Ac-H]-@6.10	ME185607	0.87	1.06
PI 38:3; [M-H]-@6.05	ME185663	0.88	1.05
PG 38:4; [M-H]-@6.03	ME185653	0.88	1.05
PG 36:2; [M-H]-@6.07	ME185649	0.88	1.05
PE 42:1; [M-H]-@9.00	ME185641	0.88	1.05
lysoPE 18:1; [M-H]-@1.83	ME185681	0.88	1.05
CL 72:3; [M-2H](2-)@7.51	ME185571	0.88	1.05
FFA(24:3)	ME185592	0.88	1.05
PC 35:2; [M-Ac-H]-@6.80	ME185606	0.87	1.05
PC 31:0; [M-Ac-H]-@6.38	ME185597	0.87	1.05
PC 33:1; [M-Ac-H]-@6.63	ME185602	0.87	1.05
PC 36:2; [M-Ac-H]-@7.05	ME185608	0.83	1.07
plasmenyl-PE 40:5; [M-H]-@7.53	ME185699	0.84	1.07
PE 37:4; [M-H]-@6.72	ME185631	0.84	1.07
plasmenyl-PE 36:3; [M-H]-@6.93	ME185690	0.84	1.07
PS 38:6; [M-H]-@5.19	ME185677	0.85	1.07
PC 40:8; [M-Ac-H]-@5.93	ME185616	0.85	1.06
FFA(18:1)	ME185579	0.85	1.06
FFA(24:0)	ME185589	0.85	1.06
PS 36:1; [M-H]-@6.67	ME185671	0.86	1.06
PE 34:0; [M-H]-@6.86	ME185619	0.86	1.06
PE 39:6; [M-H]-@6.59	ME185637	0.86	1.06
FFA(20:0)	ME185581	0.95	1.02
PE 40:5; [M-H]-@7.26	ME185639	0.96	1.02
FFA(18:0)	ME185578	0.96	1.02
PE 38:2; [M-H]-@7.53	ME185633	0.96	1.02
PE 35:1; [M-H]-@7.22	ME185625	0.90	1.04
plasmenyl-PE 34:0; [M-H]-@7.28	ME185688	0.91	1.04
PG 40:7; [M-H]-@5.10	ME185656	0.91	1.04
PC 38:5; [M-Ac-H]-@6.54	ME185612	0.91	1.04
FFA(22:0)	ME185585	0.91	1.04
lysoPE 16:0; [M-H]-@1.70	ME185679	0.91	1.04
FFA(20:2)	ME185583	0.92	1.03
FFA(16:0)	ME185577	0.94	1.03
PG 36:4; [M-H]-@5.39	ME185652	0.93	1.03
PE 36:0; [M-H]-@7.94	ME185627	0.93	1.03
PC 38:2; [M-Ac-H]-@7.76	ME185611	0.93	1.03
FFA(22:3)	ME185588	0.93	1.03
lysoPE 20:4; [M-H]-@1.33	ME185684	0.93	1.03
PE 36:5; [M-H]-@6.02	ME185630	0.64	1.16
plasmenyl-PE 40:4; [M-H]-@7.81	ME185698	0.66	1.15
plasmenyl-PE 38:2; [M-H]-@7.94	ME185693	0.65	1.15
plasmenyl-PE 42:6; [M-H]-@7.81	ME185702	0.65	1.15
CL 70:5; [M-2H](2-)@5.92	ME185570	0.67	1.14
PI 34:1; [M-H]-@5.66	ME185658	0.69	1.14
PE 38:7; [M-H]-@6.04	ME185636	0.68	1.14
plasmenyl-PE 40:2; [M-H]-@8.34	ME185696	0.68	1.14
PC 40:7; [M-Ac-H]-@6.38	ME185615	0.71	1.13
PC 38:7; [M-Ac-H]-@5.68	ME185613	0.69	1.13
PE 34:1; [M-H]-@6.87	ME185620	0.70	1.13
PE 34:3; [M-H]-@6.02	ME185622	0.70	1.13
PS 40:6; [M-H]-@5.85	ME185678	0.73	1.12
lysoPE 18:0; [M-H]-@2.47	ME185680	0.73	1.12
PG 40:8; [M-H]-@4.56	ME185657	0.73	1.12
PC 42:1; [M-Ac-H]-@9.50	ME185617	0.72	1.12
lysoPE 22:6; [M-H]-@1.27	ME185686	0.72	1.12
lysoPE 18:2; [M-H]-@1.37	ME185682	0.72	1.12
lysoPE 22:4; [M-H]-@1.87	ME185685	0.72	1.12
PC 39:6; [M-Ac-H]-@6.60	ME185614	0.75	1.11
PC 32:2; [M-Ac-H]-@5.79	ME185600	0.75	1.11
FFA(22:2)	ME185587	0.75	1.11
CerP 34:1; [M-H]-@5.97	ME185576	0.75	1.11
CL 74:7; [M-2H](2-)@6.12	ME185573	0.75	1.11
PI 38:6; [M-H]-@5.05	ME185666	0.74	1.11
PG 36:4; [M-H]-@4.85	ME185651	0.74	1.11
PG 36:3; [M-H]-@5.28	ME185650	0.74	1.11
PE 35:0; [M-H]-@7.66	ME185624	0.74	1.11
CL 78:9; [M-2H](2-)@6.71	ME185575	0.74	1.11
PA 33:2; [M-H]-@1.84	ME185593	0.74	1.11
PS 38:4; [M-H]-@5.94	ME185675	0.77	1.10
PI 36:3; [M-H]-@5.36	ME185661	0.77	1.10
plasmenyl-PE 40:3; [M-H]-@8.05	ME185697	0.77	1.10
PE 38:5; [M-H]-@6.53	ME185635	0.76	1.11
PI 36:4; [M-H]-@5.20	ME185662	0.76	1.10
FFA(18:2)	ME185580	0.76	1.10
PE 36:2; [M-H]-@6.47	ME185629	0.76	1.10
PS 34:1; [M-H]-@5.79	ME185670	0.83	1.08
plasmenyl-PE 42:5; [M-H]-@7.94	ME185701	0.82	1.08
PI 40:5; [M-H]-@5.97	ME185667	0.82	1.08
PC 37:5; [M-Ac-H]-@6.21	ME185610	0.82	1.08
FFA(20:4) Arachidonic acid	ME185584	0.82	1.08
PC 33:2; [M-Ac-H]-@6.17	ME185603	0.82	1.08
plasmenyl-PE 40:1; [M-H]-@8.74	ME185695	0.81	1.08
PS 36:2; [M-H]-@5.92	ME185672	0.81	1.08
FFA(22:1)	ME185586	0.80	1.09
plasmenyl-PE 38:5; [M-H]-@6.78	ME185694	0.79	1.09
plasmenyl-PE 38:1; [M-H]-@8.31	ME185692	0.79	1.09
PE 36:1; [M-H]-@7.48	ME185628	0.79	1.09
PE 34:2; [M-H]-@6.41	ME185621	0.79	1.09
PC 34:3; [M-Ac-H]-@5.99	ME185604	0.79	1.09
CL 74:1; [M-2H](2-)@7.51	ME185572	0.79	1.09
FFA(24:1)	ME185590	0.79	1.09
FFA(20:1)	ME185582	0.78	1.10
PI 38:4; [M-H]-@5.84	ME185664	0.78	1.10
FFA(24:2)	ME185591	0.78	1.09
plasmenyl-PE 34:3; [M-H]-@6.40	ME185689	0.78	1.09
PG 32:1; [M-H]-@5.23	ME185643	1.34	0.85
PG 36:1; [M-H]-@6.13	ME185648	1.31	0.87
PG 40:5; [M-H]-@6.04	ME185654	1.31	0.86
PC 32:1; [M-Ac-H]-@6.29	ME185599	1.17	0.93
PG 32:0; [M-H]-@5.73	ME185642	1.17	0.92
PC 30:1; [M-Ac-H]-@5.60	ME185596	1.12	0.95
PG 40:6; [M-H]-@5.58	ME185655	1.14	0.94
PG 36:0; [M-H]-@6.87	ME185647	1.13	0.94
PC 33:0; [M-Ac-H]-@7.06	ME185601	1.13	0.94
PG 33:0; [M-H]-@6.03	ME185644	1.13	0.94
plasmenyl-PE 32:0; [M-H]-@7.12	ME185687	1.10	0.96
PS 38:3; [M-H]-@6.19	ME185674	1.06	0.97
CL 78:1; [M-2H](2-)@7.97	ME185574	1.08	0.97
lysoPE 20:3; [M-H]-@1.61	ME185683	1.07	0.97
PI 40:8; [M-H]-@4.77	ME185669	1.00	1.00
PE 38:3; [M-H]-@7.28	ME185634	1.00	1.00
PC 30:0; [M-Ac-H]-@6.17	ME185595	1.00	1.00
PC 37:4; [M-Ac-H]-@6.73	ME185609	1.00	1.00
PC 32:0; [M-Ac-H]-@6.83	ME185598	1.03	0.99
PS 36:4; [M-H]-@5.31	ME185673	1.02	0.99
PC 35:1; [M-Ac-H]-@7.30	ME185605	1.05	0.98
PE 32:1; [M-H]-@6.26	ME185618	1.05	0.98
PE 38:1; [M-H]-@7.94	ME185632	1.04	0.98
PG 34:1; [M-H]-@5.80	ME185645	1.04	0.98

Factors:

F1	Diagnosis:Control
F2	Diagnosis:SIDS

Data matrix